ACVR2A and neoplasm: Interestingly, the expression of ACVR2A appeared to decline gradually with the disease progression, with the highest level of expression in the normal skin and the lowest in SCCs in all five GEP data sets (Supplementary Fig. 11), suggesting its potential tumour suppressing role in disease progression.